How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
出版年份 2023 全文链接
标题
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
作者
关键词
-
出版物
Molecular Diagnosis & Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-24
DOI
10.1007/s40291-023-00679-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
- (2023) Duaa S. Helal et al. Diagnostic Pathology
- Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials
- (2023) Christian Bolenz et al. UROLOGIA INTERNATIONALIS
- Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
- (2023) Christian Pfister et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer
- (2023) Teresa Gamba et al. Clinical Genitourinary Cancer
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
- (2022) Joaquim Bellmunt et al. CLINICAL CANCER RESEARCH
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
- (2022) Bernadett Szabados et al. EUROPEAN UROLOGY
- DNA damage repair genes alterations in genito-urinary malignancies
- (2022) Charles Dariane et al. EUROPEAN SURGICAL RESEARCH
- A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma
- (2022) Simon J. Crabb et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
- (2022) Hualin Chen et al. Frontiers in Immunology
- Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
- (2022) Elisa Tassinari et al. Cancer Management and Research
- Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
- (2022) Giuseppe Basile et al. CLINICAL CANCER RESEARCH
- Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
- (2022) Francesca Vignani et al. EUROPEAN UROLOGY
- Current best practice for bladder cancer: a narrative review of diagnostics and treatments
- (2022) Eva Compérat et al. LANCET
- Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
- (2021) Ekaterina Laukhtina et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
- (2021) P. Grivas et al. BMC CANCER
- Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
- (2021) Gottfrid Sjödahl et al. EUROPEAN UROLOGY
- Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
- (2021) Utpal Kumar et al. Journal of Laboratory Physicians
- Traditional Classification and Novel Subtyping Systems for Bladder Cancer
- (2020) Shaoming Zhu et al. Frontiers in Oncology
- Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
- (2020) Albert Font et al. Cancers
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis
- (2020) Mehdi Kardoust Parizi et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
- (2020) Ann Taber et al. Nature Communications
- Bladder Cancer
- (2020) Andrew T. Lenis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
- (2020) Denis L. Jardim et al. CANCER CELL
- Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
- (2020) Elizabeth C. Paver et al. PATHOLOGY
- Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
- (2019) Xiangli Ding et al. Cancer Management and Research
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
- (2019) Aurélie Kamoun et al. EUROPEAN UROLOGY
- Erdafitinib for the treatment of urothelial cancer
- (2019) Laura Marandino et al. Expert Review of Anticancer Therapy
- Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells
- (2019) Chang Liu et al. Nature Communications
- HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter
- (2019) Takashi Yorozu et al. Clinical Genitourinary Cancer
- Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
- (2019) Giovanni Motterle et al. European Urology Focus
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
- (2018) Feifei Teng et al. CANCER LETTERS
- Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies
- (2018) Francesco Massari et al. CANCER TREATMENT REVIEWS
- Basal subtype bladder tumours demonstrate a “hot” immunophenotype
- (2018) Anjelica Hodgson et al. HISTOPATHOLOGY
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Genomic classification and risk stratification of bladder cancer
- (2018) Damiano Fantini et al. WORLD JOURNAL OF UROLOGY
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
- (2017) Kenneth M. Felsenstein et al. Nature Reviews Urology
- HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
- (2017) Pontus Eriksson et al. Oncotarget
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer
- (2016) Andrea E. Ochoa et al. Oncotarget
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
- (2015) J. Kim et al. CLINICAL CANCER RESEARCH
- Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: A review of SEER data, 2004-2010
- (2014) Mary E. Charlton et al. CANCER
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
- (2014) S. Rebouissou et al. Science Translational Medicine
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
- (2014) E. M. Van Allen et al. Cancer Discovery
- Identification of ELF3 as an early transcriptional regulator of human urothelium
- (2013) Matthias Böck et al. DEVELOPMENTAL BIOLOGY
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
- (2013) Steven A Roberts et al. NATURE GENETICS
- A Molecular Taxonomy for Urothelial Carcinoma
- (2012) G. Sjodahl et al. CLINICAL CANCER RESEARCH
- Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches
- (2011) Francesc Pons et al. Current Oncology Reports
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started